UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 28

Sortiert nach

Cellular players in lung fibrosis

Current pharmaceutical design, 2012-09, Vol.18 (27), p.4093

2012

Volltextzugriff (PDF)

IL-22 alters gut microbiota composition and function to increase aryl hydrocarbon receptor activity in mice and humans

Microbiome, 2023-03, Vol.11 (1), p.47-47, Article 47

2023

Volltextzugriff (PDF)

Basal cells contribute to innate immunity of the airway epithelium through production of the antimicrobial protein RNase 7

The Journal of immunology (1950), 2015-04, Vol.194 (7), p.3340-3350

2015

Volltextzugriff (PDF)

Dose escalation randomised study of efmarodocokin alfa in healthy volunteers and patients with ulcerative colitis

Gut, 2023-08, Vol.72 (8), p.1451

2023

Volltextzugriff (PDF)

Astegolimab or Efmarodocokin Alfa in Patients With Severe COVID-19 Pneumonia: A Randomized, Phase 2 Trial

Critical care medicine, 2023-01, Vol.51 (1), p.103

2023

Volltextzugriff (PDF)

A phase I, randomized, ascending‐dose study to assess safety, pharmacokinetics, and activity of GDC‐8264, a RIP1 inhibitor, in healthy volunteers

Clinical and translational science, 2023-10, Vol.16 (10), p.1997-2009

2023

Volltextzugriff (PDF)

Population pharmacokinetics and pharmacodynamics of efmarodocokin alfa (IL-22Fc)

Journal of pharmacokinetics and pharmacodynamics, 2024-04, Vol.51 (2), p.141-153

2024

Volltextzugriff (PDF)

Comprehensive profiling of the human fecal proteome from IBD patients with DIA-MS enables evaluation of disease-relevant proteins

Proteomics. Clinical applications, 2024-03, p.e2300075-e2300075

2024

Volltextzugriff (PDF)

SAkuraBONSAI: Protocol design of a novel, prospective study to explore clinical, imaging, and biomarker outcomes in patients with AQP4-IgG-seropositive neuromyelitis optica spectrum disorder receiving open-label satralizumab

Frontiers in neurology, 2023-02, Vol.14, p.1114667-1114667

2023

Volltextzugriff (PDF)

Antibacterial Defense of Human Airway Epithelial Cells from Chronic Obstructive Pulmonary Disease Patients Induced by Acute Exposure to Nontypeable Haemophilus influenzae: Modulation by Cigarette Smoke

Journal of innate immunity, 2017-01, Vol.9 (4), p.359-374

2017

Volltextzugriff (PDF)

Hepatitis C Virus Targets DC-SIGN and L-SIGN To Escape Lysosomal Degradation

Journal of Virology, 2004-08, Vol.78 (15), p.8322-8332

2004

Volltextzugriff (PDF)

Viral piracy: HIV-1 targets dendritic cells for transmission

Current HIV research, 2006-04, Vol.4 (2), p.169

2006

Volltextzugriff (PDF)

Pathogens use carbohydrates to escape immunity induced by dendritic cells

Current opinion in immunology, 2004-08, Vol.16 (4), p.488-493

2004

Volltextzugriff (PDF)

Randomized Phase I Healthy Volunteer Study of UTTR1147A (IL‐22Fc): A Potential Therapy for Epithelial Injury

Clinical pharmacology and therapeutics, 2019-01, Vol.105 (1), p.177-189

2019

Volltextzugriff (PDF)

Pre-clinical and translational pharmacology of a human interleukin-22 IgG fusion protein for potential treatment of infectious or inflammatory diseases

Biochemical pharmacology, 2018-06, Vol.152, p.224-235

2018

Volltextzugriff (PDF)

Sialic Acid Mediated Endothelial and Hepatic Uptake: A Mechanism based Mathematic Model Elucidating the Complex Pharmacokinetics and Pharmacodynamics of Efmarodocokin Alfa, a Variably Glycosylated Fusion Protein

Journal of pharmaceutical sciences, 2024-07, Vol.113 (7), p.1975-1986

2024

Volltextzugriff (PDF)

Tu1861 A RANDOMIZED, OBSERVER-BLINDED PHASE IB MULTIPLE, ASCENDING DOSE STUDY OF UTTR1147A, AN IL-22FC FUSION PROTEIN, IN HEALTHY VOLUNTEERS AND ULCERATIVE COLITIS PATIENTS

Gastroenterology (New York, N.Y. 1943), 2020-05, Vol.158 (6), p.S-1192-S-1192

2020

Volltextzugriff (PDF)

Potency of HIV-1 envelope glycoprotein gp120 antibodies to inhibit the interaction of DC-SIGN with HIV-1 gp120

Virology (New York, N.Y.), 2004-11, Vol.329 (2), p.465-476

2004

Volltextzugriff (PDF)

Mucosal-targeted AIDS vaccines: the next generation?

Trends in microbiology (Regular ed.), 2004-10, Vol.12 (10), p.447-450

2004

Volltextzugriff (PDF)

Randomized Phase I Healthy Volunteer Study of UTTR 1147A ( IL ‐22Fc): A Potential Therapy for Epithelial Injury

Clinical pharmacology and therapeutics, 2019-01, Vol.105 (1), p.177-189

2019

Volltextzugriff (PDF)

SYK is a candidate kinase target for the treatment of advanced prostate cancer

Cancer research (Chicago, Ill.), 2015-01, Vol.75 (1), p.230-240

2015

Volltextzugriff (PDF)

Tu1777 - REG3A is Induced in Response to IL-22 and Correlated with Peripheral IL-22 Levels in Subjects with Inflammatory Bowel Disease

Gastroenterology (New York, N.Y. 1943), 2017-04, Vol.152 (5), p.S965-S965

2017

Volltextzugriff (PDF)

Nonclinical safety assessment of a human interleukin‐22FC IG fusion protein demonstrates in vitro to in vivo and cross‐species translatability

Pharmacology research & perspectives, 2018-12, Vol.6 (6), p.e00434-n/a

2018

Volltextzugriff (PDF)

Abstract A15: High-Content screen for inhibitors of cell migration in cancer metastasis using adenoviral knock-down

Cancer research (Chicago, Ill.), 2012-07, Vol.72 (13_Supplement), p.A15-A15

2012

Volltextzugriff (PDF)

Nonclinical safety assessment of a human interleukin‐22 FC IG fusion protein demonstrates in vitro to in vivo and cross‐species translatability

Pharmacology research & perspectives, 2018-12, Vol.6 (6)

2018

Volltextzugriff (PDF)

1 – 25 von 28

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(28)
Mit Volltextzugriff
(24)

Publikationsform

Artikel
(28)

Sprache

Englisch
(28)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(21)
Science & Technology
(21)
Humans
(18)
Animals
(9)
Mice
(6)
Pharmacology & Pharmacy
(6)
Cells, Cultured
(5)
Immunology
(5)
Interleukin-22
(5)
Biomarkers
(4)
Cytokines
(4)
Dendritic Cells - Immunology
(4)
Lectins, C-Type - Immunology
(4)
Male
(4)
Receptors, Cell Surface - Immunology
(4)
Virology
(4)
Biochemistry & Molecular Biology
(3)
Cell Adhesion Molecules - Immunology
(3)
Dc-Sign
(3)
Female
(3)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Cellular players in lung fibrosis

IL-22 alters gut microbiota composition and function to increase aryl hydrocarbon receptor activity in mice and humans

Basal cells contribute to innate immunity of the airway epithelium through production of the antimicrobial protein RNase 7

Dose escalation randomised study of efmarodocokin alfa in healthy volunteers and patients with ulcerative colitis

Astegolimab or Efmarodocokin Alfa in Patients With Severe COVID-19 Pneumonia: A Randomized, Phase 2 Trial

A phase I, randomized, ascending‐dose study to assess safety, pharmacokinetics, and activity of GDC‐8264, a RIP1 inhibitor, in healthy volunteers

Population pharmacokinetics and pharmacodynamics of efmarodocokin alfa (IL-22Fc)

Comprehensive profiling of the human fecal proteome from IBD patients with DIA-MS enables evaluation of disease-relevant proteins

SAkuraBONSAI: Protocol design of a novel, prospective study to explore clinical, imaging, and biomarker outcomes in patients with AQP4-IgG-seropositive neuromyelitis optica spectrum disorder receiving open-label satralizumab

Antibacterial Defense of Human Airway Epithelial Cells from Chronic Obstructive Pulmonary Disease Patients Induced by Acute Exposure to Nontypeable Haemophilus influenzae: Modulation by Cigarette Smoke

Hepatitis C Virus Targets DC-SIGN and L-SIGN To Escape Lysosomal Degradation

Viral piracy: HIV-1 targets dendritic cells for transmission

Pathogens use carbohydrates to escape immunity induced by dendritic cells

Randomized Phase I Healthy Volunteer Study of UTTR1147A (IL‐22Fc): A Potential Therapy for Epithelial Injury

Pre-clinical and translational pharmacology of a human interleukin-22 IgG fusion protein for potential treatment of infectious or inflammatory diseases

Sialic Acid Mediated Endothelial and Hepatic Uptake: A Mechanism based Mathematic Model Elucidating the Complex Pharmacokinetics and Pharmacodynamics of Efmarodocokin Alfa, a Variably Glycosylated Fusion Protein

Tu1861 A RANDOMIZED, OBSERVER-BLINDED PHASE IB MULTIPLE, ASCENDING DOSE STUDY OF UTTR1147A, AN IL-22FC FUSION PROTEIN, IN HEALTHY VOLUNTEERS AND ULCERATIVE COLITIS PATIENTS

Potency of HIV-1 envelope glycoprotein gp120 antibodies to inhibit the interaction of DC-SIGN with HIV-1 gp120

Mucosal-targeted AIDS vaccines: the next generation?

Randomized Phase I Healthy Volunteer Study of UTTR 1147A ( IL ‐22Fc): A Potential Therapy for Epithelial Injury

SYK is a candidate kinase target for the treatment of advanced prostate cancer

Tu1777 - REG3A is Induced in Response to IL-22 and Correlated with Peripheral IL-22 Levels in Subjects with Inflammatory Bowel Disease

Nonclinical safety assessment of a human interleukin‐22FC IG fusion protein demonstrates in vitro to in vivo and cross‐species translatability

Abstract A15: High-Content screen for inhibitors of cell migration in cancer metastasis using adenoviral knock-down

Nonclinical safety assessment of a human interleukin‐22 FC IG fusion protein demonstrates in vitro to in vivo and cross‐species translatability

Suchergebnisse filtern